Gene transfer has potential as a once-only treatment that reduces viral load, preserves the immune system and avoids lifetime highly active antiretroviral therapy. This study, which is to our knowledge the first randomized, double-blind, placebo-controlled, phase 2 cell-delivered gene transfer clinical trial, was conducted in 74 HIV-1-infected adults who received a tat-vpr-specific anti-HIV ribozyme (OZ1) or placebo delivered in autologous CD34 + hematopoietic progenitor cells. There were no OZ1-related adverse events. There was no statistically significant difference in viral load between the OZ1 and placebo group at the primary end point (average at weeks 47 and 48), but time-weighted areas under the curve from weeks 40-48 and 40-100 were significantly lower in the OZ1 group. Throughout the 100 weeks, CD4 + lymphocyte counts were higher in the OZ1 group. This study indicates that cell-delivered gene transfer is safe and biologically active in individuals with HIV and can be developed as a conventional therapeutic product.
Highly active antiretroviral therapy (HAART) has greatly improved the prognosis of individuals infected with HIV-1, but it is often associated with toxicities, adverse interactions with other drugs and the emergence of viral resistance 1 . Results from HIV-1 vaccine studies have been disappointing. In fact, increased viral replication after therapeutic or prophylactic immunization has been reported 2 . Genebased therapies, including ribozyme, antisense, aptamer, RNA interference, zinc finger nuclease, dominant-negative protein, fusion inhibitor, intracellular antibody and viral decoy approaches , have been proposed as a long-lived alternative to small-molecule HAART 10, 13, 20, 22, 24, 26, 27 . Some of these were shown to be safe in phase 1 clinical trials 4, 12, 17, 20, [28] [29] [30] . Ribozymes are small catalytic RNA molecules that can be engineered to target specific RNA sequences 10, 24, 26, 27, [31] [32] [33] and offer advantages by virtue of their specificity of target site recognition and cleavage, without any reported 'off target' effects 10, 24, 31, 34 .
OZ1 is comprised of a Moloney murine leukemia virus-based, replication-incompetent gammaretroviral vector (LNL6) containing a gene that encodes a ribozyme that targets the overlapping vpr and tat reading frames of HIV-1 ( Fig. 1a) 32, 35 . It inhibits the replication of laboratory and clinical isolates of HIV-1 in vitro, and resistance mutations in the region of HIV-1 targeted by OZ1 were not observed in long-term cell culture 10, 27, 32, 35 .
Two phase 1 clinical trials have been conducted with either CD4 + T lymphocytes 29 or CD34 + hematopoietic stem cells 4 to assess the feasibility and safety of ex vivo transduction and re-infusion of OZ1transduced cells. Both trials demonstrated that the approach was technically feasible and safe. There was no serious adverse event related to the gene transfer process or the gene transfer product during the study period or the subsequent long-term safety follow-up. Safety parameters were assessed in accordance with United States Food and Drug Administration (FDA)-Center for Biologics Evaluation and Research (CBER) recommendations 36, 37 .
Our hypothesis, tested in this study, was that OZ1-transduced CD34 + hematopoietic progenitor cells would engraft, divide and differentiate in vivo to produce a pool of mature myeloid and lymphoid cells that are protected from productive HIV-1 replication 27 . This multicenter, phase 2, randomized, double-blind, placebocontrolled clinical trial evaluated the safety and efficacy of OZ1. Each participant received a single intravenous infusion of autologous CD34 + cells without undergoing myeloablation or any form of bone marrow conditioning. Gene transfer safety parameters were assessed throughout the study in accordance with FDA-CBER guidelines 36, 37 . The protocol included two antiretroviral treatment interruptions to provide positive selective pressure for OZ1-protected cells. The impact of OZ1 on plasma HIV-1 viral load was assessed at the end of the second eight-week analytic treatment interruption (the primary endpoint). The secondary end points of quantitative marking (presence of OZ1 DNA) and expression (active RNA form of OZ1) of the gene transfer product, the time-weighted area under the curve for viral load (TWAUC), the CD4 + T lymphocyte count in absolute number and percentage of T lymphocytes (CD4%), the presence of HIV-1 proviral DNA, and thymic function (T cell receptor excision circles, TREC) were also assessed to week 100. The OZ1 treatment group participants are now enrolled in a long-term safety follow-up protocol.
RESULTS

Participants and treatment
Of 107 participants assessed for eligibility between July 2003 and January 2006, 74 were randomized to one of the two treatment groups and received OZ1-transduced (n ¼ 38) or control (n ¼ 36) CD34 + cells ( Fig. 1b) . Forty-two subjects were enrolled in the United States and 32 in Australia. The primary end point (change in viral load from baseline to the mean of week 47 and 48 of the study) was assessed in all subjects after the second treatment interruption (Fig. 1c) .
Intention-to-treat (all infused participants) and per-protocol (all participants who entered the analytic treatment interruption) populations were defined before database lock and unblinding (Fig. 2) . The baseline participant demographics and HIV-1 treatment history were comparable ( Table 1 ). The dose of granulocyte colony-stimulating factor (G-CSF) to mobilize the CD34 + cells before harvesting and the volume of the apheresis collection were similar for the two groups (data not shown). Both treatment groups received an equivalent dose of viable CD34 + cells per kg body weight. The infused cell product in the OZ1 treatment group contained a mean of 54.0% OZ1-containing cells, assessed on the basis of one vector copy per cell ( Figure 1 Ribozyme target site within HIV-1 genome, schematic of genemodified cell manufacture and protocol design. (a) The HIV-1 genome is shown together with the target nucleotide sequence. The cleavage site is indicated by an arrow; cleavage is within an overlapping region of the tat and vpr genes. (b) This is a schematic of the process. HIV-1-positive individuals received G-CSF for stem cell mobilization, peripheral blood stem cells were collected by large-volume apheresis, on days 4 and 5, and CD34 + cells were selected, cultured and then transduced with OZ1 or placebo. On day 8, the cell product was washed and infused. (c) Participants continued HAART for 24 weeks after infusion before entering a 4-week treatment interruption (weeks 24-28), which was intended to apply selective pressure on any OZ1-containing cells. The analytical treatment interruption commenced after week 40 post-infusion. Assessments were conducted weekly during the analytical treatment interruption until week 48 and then monthly until either the resumption of HAART or week 100. Figure 2 Participant disposition. At screening, a total of 28 participants were excluded; 21 did not meet eligibility criteria, and seven were excluded for other reasons, including intervening adverse events. Of the 78 participants enrolled in the study, two were withdrawn before randomization and two were withdrawn after randomization owing to cell processing failures. Three participants were lost to follow-up before the primary efficacy endpoint. A total of nine participants did not enter the analytic treatment interruption. ITT, intention to treat.
participants were lost to follow-up beforehand. The participants in the OZ1 group are now enrolled in a separate long-term follow-up protocol that will continue for at least 15 years. To date, the longest followup period from the time of infusion of the first participant is 5 years.
OZ1 gene marking and expression
We assessed OZ1 gene marking (DNA) and expression (RNA) to measure the frequency of gene-containing cells and the production of active ribozyme, respectively. At week 4 after infusion, OZ1 DNA was detected in peripheral blood mononuclear cells (PBMCs) from 94% of the participants in the OZ1 treatment group. This percentage decreased to 12% of participants tested at week 48 and 7% of participants at week 100. Data from peripheral blood cell subsets (CD4 + T cells, CD8 + T cells, B cells, monocytes and granulocytes) showed a similar decline in the percentages over time (data not shown). OZ1 DNA did not reach the quantifiable range of the assay in any blood cell sample at any time point (data not shown). The limits of detection and quantification for OZ1 DNA were 0.01% and 0.38% of cells analyzed, respectively. OZ1 RNA was detected (Z1 copy per 250 ng RNA) in PBMCs in all participants in the OZ1 treatment group at week 1. At this time point, expression was quantifiable in five participants (370-600 copies per 250 ng of total RNA); expression in the other participants was detectable but not quantifiable. OZ1 RNA was detected in 94% of these participants at week 4 and in 29% at week 48 but was not quantifiable in any sample. Of the 21 participants who remained off of HAART beyond week 48 after infusion, OZ1 RNA was detected in 15 participants. At week 100, OZ1 RNA was detected in 5 out of 12 (42%) participants for whom RNA samples were available and who continued in the treatment interruption to week 100, versus 2 of 19 (11%) participants who had resumed HAART. In some participants, insufficient RNA was available for analysis at this time point. Examples of results for the real-time quantitative PCR RNA assay and the percentages of participants in whom OZ1 DNA and RNA were detected over time have been provided online (Supplementary Figs. 1 and 2 online). Data from peripheral blood cell subsets showed a similar decline in the OZ1 expression over time (data not shown).
Primary efficacy end point
For both intention-to-treat and per-protocol populations, the mean plasma HIV-1 viral load at weeks 47 and 48 (8 weeks after entering the analytic treatment interruption) was lower in the OZ1 group, but the difference was not statistically significant ( Table 2 ). The number of participants with a plasma viral load of fewer than 1 Â 10 4 (4 log 10 ) copies per ml at weeks 47 and 48 (15 of 32) was greater in the OZ1 group than in the control group (5 of 33; P ¼ 0.009). In the perprotocol OZ1 population, the correlation between the dose of CD34 + cells infused per kg body weight and the viral load at weeks 47 and 48 was weakly negative (rho À0.319; P ¼ 0.076). There was no such negative correlation in the control group (rho 0.188; P ¼ 0.312).
Secondary efficacy end points
The viral load data from the analytic treatment interruption beginning at week 40 were used to calculate the TWAUC (Fig. 3) . The TWAUC in the per-protocol population was significantly lower in the OZ1 group (weeks 40-48: median difference -0.34 log 10 copies per ml per day, P ¼ 0.024; weeks 40-100: median difference -0.37 log 10 copies per ml per day, P ¼ 0.034; Table 2 ). The number of participants with a TWAUC in the lowest quartile during weeks 40-100 was significantly larger in the OZ1 group (OZ1 n ¼ 12, 37.5%; control n ¼ 5, 15.2%; P ¼ 0.04). The median times to reach viral loads of 3 log 10 , 4 log 10 and 5 log 10 copies per ml during the analytic treatment interruption in the per-protocol population were longer in the OZ1 group. However, a statistically significant difference was observed only for the time to reach a viral load of 4 log 10 copies per ml ( Table 2) .
During the analytic treatment interruption, 17 (45%) participants in the OZ1 group reinitiated HAART, compared to 22 (61%) control participants. For the participants in the control group, the median time to re-initiation of HAART was 29.4 weeks (n ¼ 22, 61%), and for the OZ1 group it was more than 60 weeks. This difference between treatment groups was not statistically significant.
Both treatment groups showed peripheral blood lymphodepletion related to G-CSFinduced mobilization and large volume apheresis [38] [39] [40] (Fig. 4 and Supplementary  Fig. 3 online) . The relationship between viral load and CD4 + count was similar for both treatment groups. For the per-protocol population, the CD4 + lymphocyte counts (in mean number of cells per ml and percentage of T lymphocytes) were 476 and 27% in the OZ1 group compared to 437 and 24% in the control group at weeks 47 and 48 and 490 and 28% (OZ1) and 441 and 25% (control) at week 100. Analysis of the percentage of CD4 + and CD8 + T lymphocytes showed higher CD4 + cell counts and correspondingly lower CD8 + cell counts in the OZ1 group (Fig. 4a-c) . CD4 + lymphocyte recovery was also examined in participants who recommenced HAART. In both treatment groups, once HAART was recommenced, the percentage of CD4 + T lymphocytes increased toward the baseline until week 100 (Fig. 4d) . The median decrease in CD4 + T lymphocyte count from baseline at week 100 was approximately 100 cells per ml (Fig. 4d) .
Exploratory analysis of the primary end point at weeks 47 and 48 was performed in the subset of participants who continued to show OZ1 expression in PBMCs at any time point beyond week 48. The median plasma viral load in these OZ1-treated participants (3.81 log 10 , 95% confidence interval 3.18-4.23, n ¼ 15) was significantly lower than in the control participants (4.58 log 10 , 95% confidence interval median 4.31-4.83, n ¼ 33; P ¼ 0.003). The median TWAUC from weeks 40-48 in these OZ1-treated participants (3.44 log 10 copies per ml per day, n ¼ 15) was significantly lower than in the control participants (3.93 log 10 copies per ml per day, n ¼ 33; P ¼ 0.03) as was the median TWAUC from weeks 40-100 (3.97 log 10 copies per ml per day, n ¼ 15) in comparison to the control group (4.53 log 10 copies per ml per day, n ¼ 33; P ¼ 0.005). Although the HIV-1 viral load in the OZ1 expressors were lower than the non-OZ1 expressors, this difference was not statistically significant. Figure 3 HIV-1 viral load: ITT population. Quantification of the mean viral load, as determined by real-time assay results. Because participants recommenced HAART at different times, the n values at the different time points have been included. PCR sequence data of the HIV-1 protease and reverse transcriptase genes were used to generate a virtual phenotype. Similar data were seen for the perprotocol population. Only one participant with a mutation associated with resistance to protease inhibitors failed to suppress HIV-1 replication after the recommencement of HAART. Screening visit is indicated as scr.
Safety evaluations
There was no death or clinically severe cardiovascular, renal or hepatic adverse event reported for randomized participants (Supplementary Table 1 online). All three participants who experienced a serious adverse event were in the control group (Supplementary Table 1 ). None of these serious adverse events was assessed as being related to G-CSF, leukapheresis, cell infusion or other study procedures. Most participants (99%) experienced at least one G-CSFassociated adverse event such as musculoskeletal pain (92%) or headache (32%) ( Supplementary Table 1 ). Three participants, two of whom were in the OZ1 treatment group, developed transient hepatomegaly associated with G-CSF administration; 69% and 77% of all participants had transient elevations of aspartate aminotransferase and alanine aminotransferase, respectively, again associated with G-CSF. One participant in the OZ1 group developed a grade 4 elevation of aspartate aminotransferase at week 40; however, it returned to within the normal range by week 48 of the study. Six participants (OZ1, n ¼ 2; control, n ¼ 4) experienced asymptomatic grade 3 thrombocytopenia after apheresis. One of the OZ1 participants required a platelet transfusion. Three participants experienced thrombocytopenia associated with the first interruption of HAART. In all three cases, platelet counts returned to normal after recommencement of HAART. Three participants (OZ1, n ¼ 1; control, n ¼ 2) developed grade 3 neutropenia; two recovered to the normal range by the next visit. One participant had two episodes of grade 3 neutropenia (0.62 Â 10 3 and 0.65 Â 10 3 cells per ml) at weeks 20 and 64 after infusion, after which time neutrophil counts returned to baseline levels. Severe adverse events associated with communityacquired infections were reported in both groups (OZ1, n ¼ 2, 5.3%; control, n ¼ 3, 8.3%) and consisted of cases of influenza, oral herpes simplex and tonsillitis. Mild to moderate cases of oral candidiasis (total n ¼ 4) and oral hairy leukoplakia (total n ¼ 2) developed during periods of antiretroviral interruption equally in participants from both groups. CD4 + lymphocyte counts at the time of these events ranged from 342-467 cells per ml and 19-36% of T lymphocytes.
No predominant integration site determined by linear amplified mediated PCR (LAM-PCR) or replication-competent retrovirus was detected at any time point. No hematopoietic cell clonal expansion or other event suggestive of insertional mutagenesis was observed (data not shown). The OZ1 target sequence in the HIV-1 plasma RNA was assessed over time. Individual variation in nucleotide sequence was detected in 9 of 63 participants for whom sequence data was available from more than one visit (OZ1, n ¼ 5 of 35, 14.3%; control, n ¼ 4 of 28, 14.3%). None of these changes was a modification at the ribozyme recognition site to prevent cleavage, nor did any of them suggest the evolution of resistant virus. 
DISCUSSION
The present study is, to our knowledge, the largest cell-delivered gene therapy trial conducted to date and the only randomized, controlled phase 2 study of a potential cell-delivered gene therapeutic. Although the primary efficacy end point was not reached, HIV-1 viral loads were consistently lower in the OZ1 treatment group for all analyses. Statistically significant differences were observed between treatment groups for the number of participants with a viral load of less than 4 log 10 copies per ml at week 47 and 48, for the per-protocol TWAUC weeks 40-48 and weeks 40-100, for the number of participants in the lowest quartile of TWAUC weeks 40-100 and for the time to a viral load of 4 log 10 copies per ml in the analytic treatment interruption group. The impact of OZ1 on HIV-1 viral load is further supported by the correlation of viral load with OZ1 expression beyond week 48 with CD34 + cell dose. The CD4 + and CD8 + T lymphocyte count data were consistent with the HIV-1 viral load differences between the treatment groups. Target site sequencing showed no evidence for the development of resistance to OZ1 during this 100-week study. This lack of resistance may be due to the low percentage of gene-marked cells, the production of a less fit virus due to mutation(s) in the highly conserved region targeted by OZ1 (ref. 32 ), or both. Mathematical modeling undertaken before this clinical study (G.P.S., G.C. Fanning, J.L.M., L.A.E. and S.M.P. et al., unpublished data) predicted that during the analytic treatment interruption OZ1 recipients would experience an initial increase in HIV-1 viral load followed by the establishment of a lower set point. The model predicted that the establishment of OZ1 CD34 + cells in the bone marrow at 10-20% of total CD34 + cell population could reduce viral load by 0.5 log 10 in one year. In this phase 2 study, bone marrow aspiration was not performed because it is invasive and would present additional risk, particularly for the control participants; thus, the percentage engraftment is not known. On the basis of the frequency of cells containing OZ1 (0.01-0.38%) in the peripheral blood, it can be inferred that engraftment was substantially lower than 10-20%. Previous studies have also shown that, in the absence of strong selective pressure, peripheral blood reconstitution from genetransduced hematopoietic stem cells is limited [41] [42] [43] [44] . Given the engraftment and gene expression results in this study, the biological effect of OZ1 was greater than predicted by the modeling. Candidate mechanisms for this additional effect include an impact of OZ1 on cell-to-cell transmission in the lymphatic system; compartmentalization such that the number of OZ1-containing cells in the peripheral blood is not representative of the survival of OZ1-containing cells in sequestered discrete foci (for example, the bone marrow and lymphatic system, in particular the gut-associated lymphoid tissue) and the protection of particular cell subpopulations such as antigen-presenting cells (including dendritic cells and macrophages) or HIV-specific CD4 + T lymphocytes. Improvements in mobilization, CD34 + cell collection and transduction compared to the phase I study 8 resulted in a mean transduced CD34 + cell dose of 5 Â 10 6 cells per kg body weight and an increase in the frequency of OZ1-containing cells in the peripheral blood (approximate 2 log 10 ). The peripheral blood lymphodepletion observed here has been described after large-volume apheresis 38, 39 . As with those studies, the protracted recovery seems to be limited to the T lymphocyte population. This may reflect slow thymic production, shortened lifespan of mature T lymphocytes, or both. The protracted lymphocyte recovery in this study was exacerbated during the antiretroviral treatment interruptions. In the future, modifications would aim to increase the dose, improve homing to the bone marrow, engraftment and differentiation through the myeloid and lymphoid compartments of transduced CD34 + cells, and develop a more potent construct.
In this phase 2 study, as in the phase 1 trials 4, 29 , no safety concerns associated with OZ1 gene transfer were identified. All serious adverse events were unrelated to study procedures or study drug infusion. Notably, no death, AIDS-defining event, severe infection or clinically significant cardiovascular, renal or hepatic event was reported in randomized participants.
The increased morbidity and mortality associated with the cessation of HAART observed during the Strategies for Management of Antiretroviral Therapy (SMART) study became known during the course of this study 45 . Specific discussions regarding the safety of the treatment interruptions in the OZ1 protocol were conducted with the Data Safety Monitoring Board and the Institutional Review Boards. The strict entry criteria met by all participants, the stringent monitoring of participants and the provision for investigators to reintroduce HAART at any stage distinguish this OZ1 trial from the SMART study. Future HIV-1 gene therapy trials could be designed to study participants before the initiation of HAART, obviating the need for treatment interruptions.
This study supports our concept that OZ1-transduced CD34 + cell therapy is safe and has efficacy, albeit modest. It shows the potential of the gene therapy approach for the treatment of HIV-1 and represents a major advance in the field.
METHODS
Participants and blinding. We randomly allocated 74 early-stage, HIV-1infected participants aged 18 to 45 to groups receiving either OZ1-transduced or control-treated CD34 + cells. We gave each participant a single intravenous infusion of autologous cells without myeloablation or other conditioning. The inclusion and exclusion criteria are described in the main text and Supplementary Methods. The sponsor, investigators, site staff, laboratory staff and participants were all blinded to the treatment group assignment.
OZ1 and control manufacture. OZ1 is an LNL6-based retroviral vector containing a ribozyme encoded by the DNA sequence 5¢-TTAGGATCCTGAT GAGTCCGTGAGGACGAAACTGGCTC-3¢. Manufacturing was performed by BioReliance Corporation under Good Manufacturing Practice conditions. We collected the OZ1 gene transfer product as the supernatant of AM-12/RRz2 retrovirus-producer cells; we also produced a media-only control.
Cell collection and CD34 + cell processing. We treated participants for 5 consecutive days with G-CSF (30 mg per kg body weight per day) to mobilize CD34 + cells, which we collected by large-volume apheresis using either manual or automatic setting (approximately 20 liters) on both days 4 and 5. We selected and cultured CD34 + cells in the presence of stem cell factor (Amgen) and megakaryocyte growth and differentiation factor (Takara) (SCF-MGDF) for 30-36 h to recruit cells into the cell cycle in preparation for retroviral transduction with OZ1 or placebo in the presence of RetroNectin (Takara) and SCF-MGDF. On day 8, we washed the gene-modified cell product, prepared it for infusion and tested it for purity, potency and sterility before infusion. All participants received their autologous cell product as per the randomization. We set the day of infusion as day 0.
Protocol design. This 100-week, 45-visit study recruited participants whose viral load was suppressed by HAART. The study design included two periods of antiretroviral treatment interruption (weeks 24-28 and weeks 40-48). The second antiretroviral treatment interruption, termed the analytic treatment interruption, was allowed to continue until week 100 unless protocol-defined limits were reached. At any stage in the protocol, the local physician investigator could advise a participant to reinitiate therapy.
Assessments were conducted weekly during the analytical treatment interruption until week 48 and then monthly until either the resumption of HAART or week 100. Participants were advised to recommence HAART if the protocoldefined viral load limits were reached: 500,000 copies per ml (up to week 48) and 100,000 copies per ml (weeks 48-100). HAART was also recommenced if protocol-defined limits for CD4 + lymphocyte counts (o150 cells per ml) were reached or if the participant developed an opportunistic infection. Participants who recommenced HAART were scheduled to attend three monthly visits.
We tested HIV-1 viral load with the Roche Amplicor HIV-1 Monitor Assay (range 400-750,000 copies per ml) in real time. We assessed efficacy parameters both in real time and in batch testing by a single laboratory of stored frozen plasma samples.
We performed safety evaluations on all participants who were randomized. We took blood samples throughout the study for analysis of the sequence of the tat-vpr RNA in the region targeted by OZ1. We performed HIV-1 genotyping at the end of each treatment interruption by PCR sequencing of the genes encoding viral protease and reverse transcriptase (Virco Virtual Phenotype). We tested for the emergence of a predominant OZ1-containing clone on PBMCs by LAM-PCR integration analysis at Cincinnati Children's Hospital Medical Center 46 in 6-month intervals. We evaluated replication-competent retrovirus by PCR with primers specific for the amphotropic retroviral envelope.
We conducted this study in accordance with International Conference on Harmonization-Good Clinical Practice. We obtained approval for the study from the individual Institutional Review Boards and Institutional Biosafety Committees at each site participating in this trial. Approval was also obtained from the US Food and Drug Administration (Center for Biologics Evaluation Review), the US National Institutes of Health (Recombinant DNA Advisory Committee) and the Therapeutic Goods Administration and the Office of Gene Technology Regulator in Australia. The study was listed on a public clinical trial registry at http://www.clinicaltrials.gov/; NCT00074997.
Statistical analyses. We did not perform statistical analysis on the baseline data. For the analyses of efficacy, we defined two populations. The intention-to-treat population was predefined as all participants who were randomized and received the cell infusion. The per-protocol population was defined as all participants who completed the first 4-week treatment interruption, recommenced HAART and entered the analytic treatment interruption. We made formal group comparisons of continuous primary and secondary parameters with the Wilcoxon rank-sum test with 95% confidence intervals provided for the medians and the difference in the medians (calculated with PROC STATXACT in SASA and the Hodges-Lehman estimate). We analyzed binary endpoints with Fisher's exact test with 95% confidence intervals. Participants for whom data were unavailable, owing to either noncompliance with the protocol or withdrawal before the analytic treatment interruption, were included in formal comparisons by being ranked as having the joint-worst outcome for continuous end points or being categorized as failures for binary end points. Participants who recommenced HAART before week 48 had an imputed value-the last value recorded, assigned and carried forward to week 48. We also performed analyses without imputation.
We derived the primary end point-the mean plasma viral load at weeks 47 and 48-by taking the mean viral load per participant at weeks 47 and 48. We calculated the TWAUC by linear trapezoidal integration on the logged transformed data. For time to resumption of HAART, we included participants who did not start the analytic treatment interruption in analyses with a time of zero, whereas participants who did not resume HAART before week 100 had the time to resumption of HAART included in analyses as a censored observation, and we assessed statistical significance with the log-rank test.
In all analyses, we took statistical significance at the two-sided 5% level, with no adjustment for multiple secondary parameters and analyses. Zolopa. We also acknowledge the contribution of the leukapheresis collection and cell processing staff, W. Quan for assistance with quality assurance and A. Miller of the Biologics Group for assistance with regulatory aspects. S. Margrie had a key role in the development of the statistical analysis plan and in the statistical analyses. C. Ang and A. King assisted with the preparation of the manuscript. We acknowledge W. Gerlach, D. Wade, J. Peacock, R. de Feyter and L. Farrell for their vital role during the early stages of the development of OZ1. We sincerely thank the participants who enrolled in this intensive study and the members of the Data Safety Monitoring Board. The University of California-Los Angeles Center for AIDS Research and University of California-Los Angeles General Clinical Research Center were supported by US National Institutes of Health grants AI28697 and M01-RR00865.
